Skip to content

'LIFEView' Audiovisual Technology: Virtual Travel to Support Wellbeing and Quality of Life at the End of Life

'LIFEView' Audiovisual Technology: Virtual Travel to Support Wellbeing and Quality of Life at the End of Life

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04030910
Enrollment
38
Registered
2019-07-24
Start date
2019-10-16
Completion date
2022-12-31
Last updated
2023-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative Care, Psychological Distress, Quality of Life, Terminal Illness

Keywords

Life review, Reminiscence, Technology, Existential distress, Virtual travel, Well-being

Brief summary

This study is looking to assess the use of an audio-video technology called 'LIFEView' using a laptop and large-screen TV. This tool intends to support life review or reminiscence of past experiences, escape from current surroundings using virtual travel, or virtual visits to a location that one might have liked to visit in their lifetime but could not. We hope that by using this technology, we can support better wellbeing and quality of life for patients receiving palliative care services within the community and on an inpatient palliative care unit, or for patients at the end-of-life within Bruyère long-term care homes. Due to the potential for disorientation and reduced physical mobility, patients receiving palliative and end-of-life care may be unable to fully enjoy an immersive experience using a virtual reality (VR) headset. To reduce the possibility of disorientation that may arise from using a VR headset with 'LIFEView', our research team will use the 'LIFEView' prototype software loaded on a laptop and connected to a mobile high-definition 50 TV for inpatient PCU and LTC facility use, or to a patient's personal TV within their residence in the community. This setup will also improve accessibility to 'LIFEView' as a result of its relatively low-tech requirements (i.e. TV + laptop), and allows for an opportunity for patients and their loved ones to share cherished memories and stories.

Detailed description

This project is designed to address the psychosocial and existential suffering commonly experienced by palliative care patients. Technology-based reminiscence and dignity therapy interventions have been demonstrated to improve well-being and quality of life in older adults (Lazar et al, 2014), although little evidence exists to support the use of these technology-based interventions in a palliative care context. These technologies may require modification to meet the needs of PEOLC patients that are at risk for delirium, a neuropsychiatric condition characterized by fluctuating disruptions in awareness, focus and cognition (American Psychiatric Association, 2013). Delirium can be experienced by up to 88% of patients at the end of life (Hosie et al., 2013). Moreover, patients in PEOLC settings may also have limited mobility or may be bedbound. Due to the potential for disorientation and reduced physical mobility, patients receiving PEOLC may be unable to fully enjoy an immersive experience using a virtual reality (VR) headset. To reduce the possibility of disorientation that may arise from using a VR headset with 'LIFEView', our research team plans to use the 'LIFEView' prototype software loaded on a laptop and connected to a mobile high-definition 40-42 TV for inpatient PCU and LTC facility use, or to a patient's personal TV within their residence in the community.

Interventions

OTHER'LIFEView'

A prototype audiovisual technology in development by Motitech AS.

Sponsors

Bruyere Continuing Care
CollaboratorUNKNOWN
Bruyère Health Research Institute.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

All eligible patients will be recruited to receive the intervention (LIFEView).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Any patients who are able to complete the outcome measures (Section 5.0 Outcomes) and capable of consenting to participating in the research study will be included.

Exclusion criteria

Patients experiencing the following, as determined by the clinical care team: * Delirium * Severe cognitive impairment (as determined by the clinical care team) * Known behavioural abnormalities (e.g. overtly aggressive behavior) that in the opinion of the clinical care team might impede any meaningful participation in the project * A score of \<30% on the Palliative Performance Scale (PPS) (Anderson et al., 1996) at the time of consent * Individuals who are already currently using Motiview paired with a exercise bicycle in the LTC setting * Those who are in the opinion of attending physician or clinical team too unwell to participate in the project * Unable to complete outcome measures indicated

Design outcomes

Primary

MeasureTime frameDescription
Change in psychological and physical symptoms measured by the Edmonton Symptom Assessment System-revised (ESAS-r) (Bruera et al., 1991; Watanabe et al., 2011)At least 24 hours before using 'LIFEView', and directly after and 48 hours after using 'LIFEView' (pre- and post-'LIFEView')The ESAS-r is a 9-item symptom assessment tool that assesses pain, tiredness, drowsiness, nausea, lack of appetite, shortness of breath, depression, anxiety, and feeling of wellbeing. Each item is rated by patients on a 0-10 scale (0= best possible, 10= worst possible).

Secondary

MeasureTime frameDescription
Change in quality of life measured by the McGill Quality of Life-Revised questionnaire (Cohen et al., 2017)At least 24 hours before using 'LIFEView', and 48 hours after using 'LIFEView' (pre- and post-'LIFEView')The MQOL-R will be used to assess patient quality of life. There are 4 parts to the questionnaire on overall quality of life, physical symptoms, feelings and thoughts, and social aspects of the participant's life. Each statement is rated on a 0-10 scale (0= worst possible,10= best possible).
Psychosocial effects and aspects of quality of life as determined by semi-structured interviews for consenting participants and their consenting family member(s) or caregiver(s).Within 24 hours of using 'LIFEView' (post-'LIFEView')These interviews will explore the impact of the 'LIFEView' intervention on patient quality of life, patient-family and patient-caregiver interactions, perceptions of the 'LIFEView' intervention as a tool to improve well-being and quality of life in palliative care settings, and feasibility of using volunteer services to support the long-term sustainability of this intervention across care settings.
Change in heart rateAt least 24 hours before using 'LIFEView', and directly after using 'LIFEView' (pre- and post-'LIFEView')Heart rate (beats per minute; bpm) will be measured using a wireless cuff.
Change in blood pressureAt least 24 hours before using 'LIFEView', and directly after using 'LIFEView' (pre- and post-'LIFEView')Blood pressure (mm Hg) will be measured using a wireless cuff.

Other

MeasureTime frameDescription
Aspects of participant's level of general well-being as per the Greater Cincinnati Chapter Well-Being Observation tool (Rentz, 2002; Kinney & Rentz, 2005) during the 'LIFEView' session, and other observable phenomenaFrom initiation of the 'LIFEView' session and directly after using 'LIFEView' (during and post-'LIFEView')The Greater Cincinnati Chapter Well-Being Observation tool will be used by the research team members to assess each patient's state of general well-being. There are 6 domains, for which each statement is rated on a 0-4 scale (0= never, 1= rarely, 2= some of the time, 3= most of the time, 4= always). Observational field notes will be taken by the Research Coordinator during the course of study participation on observable phenomena before, during, and after the 'LIFEView' session (e.g. verbalized reminiscence, feelings… etc.). Patients and their family members will only be identified by their participant study ID in field notes.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026